Inhibition of Integrin αvβ6 Activation of TGF-β Attenuates Tendinopathy

Area of Science:

• Musculoskeletal biology
• Cellular and molecular mechanisms of disease
• Integrin signaling pathways

Background:

• Tendinopathy is a prevalent tendon disorder causing pain and functional impairment.
• Current therapies for tendinopathy lack efficacy and have poorly understood mechanisms.
• Identifying the molecular drivers of tendinopathy is crucial for developing effective treatments.

Purpose of the Study:

• To elucidate the cellular and molecular mechanisms underlying tendinopathy.
• To investigate the role of transforming growth factor-beta (TGF-β) and integrin αvβ6 in tendinopathy.
• To explore potential therapeutic targets for tendinopathy.

Main Methods:

• Utilized mouse models of tendinopathy with transgenic expression of active TGF-β.
• Administered TGF-β neutralizing antibodies and performed inducible knockout of Tgfbr2 in tenocytes.
• Generated conditional knockout mice for the integrin αv gene in tendons.
• Analyzed tenocyte phenotype transition and TGF-β activation in response to mechanical load.

Main Results:

• Excessive active TGF-β was observed during tendinopathy progression, inducing tenocyte-to-chondrocyte transition.
• Transgenic active TGF-β induced spontaneous tendinopathy, while antibody treatment attenuated it.
• Inhibition of Tgfbr2 in tenocytes and knockout of integrin αv in tendons prevented tendinopathy.
• Integrin αvβ6 was identified as a key activator of TGF-β in tendons under mechanical load.

Conclusions:

• Integrin αvβ6-mediated activation of TGF-β is a critical mechanism driving tendinopathy.
• Targeting the integrin αvβ6-TGF-β pathway presents a promising therapeutic avenue for tendinopathy.
• This study provides novel insights into the molecular pathogenesis of tendinopathy.